Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their interests in Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in shareholdings for several executives following the re-investment of dividends paid on April 12, 2012. The shares were purchased at a price of 1,467.31 pence per share on April 19, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in Ordinary Shares via dividend re-investment.
- Transaction Date: April 19, 2012.
- Share Price: 1,467.31 pence per share.
- Dividend Date: April 12, 2012.
- Notable Holders: Includes Dr. M M Slaoui (342,385 shares), Mr. E J Gray (526,549 shares), and Mr. C Weber (328,306 shares), among others.